Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|November 1, 2019
Investing in Cell and Gene Technology
Author(s)Pharmaceutical Technology Editors
A number of experts will be examining investment opportunities within the evolving cell and gene therapy sector, in a panel discussion on Wednesday morning (Nov. 6, 2019) during CPhI Worldwide in Frankfurt, Germany.
Advertisement
A number of experts will be examining investment opportunities within the evolving cell and gene therapy sector, in a panel discussion on Wednesday morning (Nov. 6, 2019) during CPhI Worldwide in Frankfurt, Germany.
As cell and gene therapies are garnering more interest within the industry and finding use for the treatment of patients who had previously unmet needs, regulators have started to prepare for increased products in the sector. As a result of the sector’s potential, it is inevitable that there will be a certain degree of commercial opportunities available for companies.
In the panel discussion, experts will specifically look at the sector outlook, long-term opportunities, potential challenges in commercialization and pricing, the right investments for contract development and manufacturing organizations, and dynamics of logistics and supply. The panel will include, Fatma Aybegum Senkesen (Lonza), Fiona Barry (PharmSource-a GlobalData Product), Dr. Malte Kremer (Strategy&), Andy Lewin (Oxford BioMedica), Paolo Morgese (ALira Health), Chris Murphy (Thermo Fisher Scientific), Angela Tsang Myers (MilliporeSigma), and Dr. Thomas VanCott (Paragon Bioservices).
Understanding the Cell & Gene Technology Opportunity
Wednesday Nov. 6, 2019
10:30–11:40
ICSE Theatre (120D40)
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement